ARIZ Precision Medicine is developing potentially curative drugs that selectively deliver fatal genetic messages to cancer cells at the right place, the right time and at the right dose -specifically targeting the gene and protein responsible for cancer initiation while at the same time sparing healthy cells. ARIZ combines biological (RNA-based) payloads that target and modify epigenetic drivers of cancer (PRDM family of genes/proteins) with targeted drug delivery systems that recognize cell surface ligands unique to cancer cells. This innovative combination stops the disease initiator, while at same time has lower risk of side effects.
Learn more about ARIZ:
Ariz’s EIR: Louise Kirkbride